*By Bridgette Webb*
Drugmaker Merck announced earlier this month it will slash prices on several drugs by 10 percent or more.
But there is a catch: the price rollback will only affect some of the smaller products in its portfolioーlike Hepatitis C drug, Zepatier, which accounts for about 4 percent of the company's salesーand not top sellers like cancer treatment Keytruda.
"Their scope is relatively limited," said Peter Loftus, a Reporter for the Wall Street Journal, during an interview on Cheddar Monday. "If you think about the total sales that Merck generatesーit's a relatively small percentage."
Merck's announcement was met with praise from the Trump administration. Health and Human Services Secretary Alex Azar claimed the drop in prices was spurred by Trump's latest crackdown on pharmaceutical companies.
Other big pharma names are following suit: Pfizer and Novartis announced they will freeze price increases for the rest of the year, earning them congratulatory tweets from the president.
Despite all of the price freezes and drops, Loftus says that patients may not actually see any real savings.
"I don't think you can say on a widespread basis, and really for the average drug or patient, that prices are coming down, there are still price increases."
For the full segment, [click here.]
(https://cheddar.com/videos/drugmakers-tout-lower-prices)
A new gel that helps stop bleeding for both emergency care and surgical procedures in animal medicine is being sought for FDA approval for a human version.
In this photo provided by Henry Danner, Omari Maynard sits with his children, Khari, left, and, Anari, holding a photo of their late mother, Shamony Gibson, at home in the Brooklyn borough of New York on April 9, 2022. Gibson passed away in 2019, two weeks after giving birth to Khari due to a pulmonary embolism. “She wasn’t being heard at all,” said Maynard, an artist who now does speaking engagements as a maternal health advocate.
The Environmental Protection Agency has proposed a new plan to lower the cap on the amount of harmful "forever chemicals" allowed in drinking water across the country.
Dr. Joel Salinas, clinical assistant professor of neurology at NYU Langone Health and chief medical officer at Isaac Health, spoke with Cheddar News anchor Shannon LaNier about Alzheimer's disease and struggles to find an effective treatment.
